Select Regional / Country Report

North America Cell and Gene Therapy Manufacturing QC Market Size, Share & Trends Analysis Report By Therapy Type (Cell Therapy, CAR-T, CAR-NK, B-Cell, Others, Gene Therapy, Viral, Non-viral), By Scale (Pre-commercial/ R&D Manufacturing, Commercial Scale Manufacturing), By Mode (Contract Manufacturing, In-house Manufacturing), By Workflow (Cell Processing, Cell Banking, Fill & Finish Operations, Raw Material Testing, Vector Production, Other Workflows), By Process (Upstream Processes, Downstream Processes), By End-User (Pharmaceutical Companies, Biopharmaceutical / Biotechnological Companies, Contract Manufacturing Organizations), By Technology Type (Fluorescence-Activated Cell Sorting (FACS), Enzyme-Linked Immunosorbent Assay (ELISA), Chromatography, Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Others) and By Country(U.S., Canada) Forecasts, 2025-2033

Report Code: SRHI56477DR

Last Updated : October 21, 2024

Author : Straits Research

Starting From

USD 2300

Buy Now

Download Free Sample

Table Of Content

Executive Summary

Research Scope & Segmentation

Research Objectives
Limitations & Assumptions
Market Scope & Segmentation
Currency & Pricing Considered

Market Opportunity Assessment

Emerging Regions / Countries
Emerging Companies
Emerging Applications / End Use

Market Trends

Drivers
Market Warning Factors
Latest Macro Economic Indicators
Geopolitical Impact
Technology Factors

Market Assessment

Porters Five Forces Analysis
Value Chain Analysis

ESG Trends

ESG Trends

North America Market Analysis

Introduction
By Therapy Type
1. Introduction
  1. Therapy Type By Value
2. Cell Therapy
  1. By Value
  2. CAR-T
    1. CAR-T By Value
    2. Autologous CAR-T
      1. Autologous CAR-T By Value
    3. Allogeneic CAR-T
      1. Allogeneic CAR-T By Value
  3. CAR-NK
    1. CAR-NK By Value
    2. B-Cell
      1. B-Cell By Value
    3. Other
      1. Other By Value
3. Gene Therapy
  1. By Value
  2. Viral
    1. Viral By Value
    2. AAV
      1. AAV By Value
    3. Lentiviral vectors
      1. Lentiviral vectors By Value
    4. Other
      1. Other By Value
  3. Non-Viral
    1. Non-Viral By Value
By Scale
1. Introduction
  1. Scale By Value
2. Pre-commercial/ R&D Manufacturing
  1. By Value
3. Commercial Scale Manufacturing
  1. By Value
By Mode
1. Introduction
  1. Mode By Value
2. Contract Manufacturing
  1. By Value
3. In-house Manufacturing
  1. By Value
By Workflow
1. Introduction
  1. Workflow By Value
2. Cell Processing
  1. By Value
3. Cell Banking
  1. By Value
4. Fill & Finish Operations
  1. By Value
5. Raw Material Testing
  1. By Value
6. Vector Production
  1. By Value
7. Other Workflows
  1. By Value
By Process
1. Introduction
  1. Process By Value
2. Upstream Processes
  1. By Value
3. Downstream Processes
  1. By Value
By End-User
1. Introduction
  1. End-User By Value
2. Pharmaceutical Companies
  1. By Value
  2. Small Size
    1. Small Size By Value
  3. Medium Size
    1. Medium Size By Value
  4. Large Size
    1. Large Size By Value
3. Biopharmaceutical / Biotechnological Companies
  1. By Value
  2. Small Size
    1. Small Size By Value
  3. Medium Size
    1. Medium Size By Value
  4. Large Size
    1. Large Size By Value
4. Contract Manufacturing Organizations
  1. By Value
  2. Small Size
    1. Small Size By Value
  3. Medium Size
    1. Medium Size By Value
  4. Large Size
    1. Large Size By Value
By Technology Type
1. Introduction
  1. Technology Type By Value
2. Fluorescence-Activated Cell Sorting (FACS)
  1. By Value
3. Enzyme-Linked Immunosorbent Assay (ELISA)
  1. By Value
4. Chromatography
  1. By Value
5. Next-Generation Sequencing (NGS)
  1. By Value
6. Polymerase Chain Reaction (PCR)
  1. By Value
7. Others
  1. By Value
U.S.
1. By Therapy Type
  1. Introduction
    1. Therapy Type By Value
  2. Cell Therapy
    1. By Value
    2. CAR-T
      1. CAR-T By Value
      2. Autologous CAR-T
        
        Autologous CAR-T By Value
      3. Allogeneic CAR-T
        
        Allogeneic CAR-T By Value
    3. CAR-NK
      1. CAR-NK By Value
      2. B-Cell
        
        B-Cell By Value
      3. Other
        
        Other By Value
  3. Gene Therapy
    1. By Value
    2. Viral
      1. Viral By Value
      2. AAV
        
        AAV By Value
      3. Lentiviral vectors
        
        Lentiviral vectors By Value
      4. Other
        
        Other By Value
    3. Non-Viral
      1. Non-Viral By Value
2. By Scale
  1. Introduction
    1. Scale By Value
  2. Pre-commercial/ R&D Manufacturing
    1. By Value
  3. Commercial Scale Manufacturing
    1. By Value
3. By Mode
  1. Introduction
    1. Mode By Value
  2. Contract Manufacturing
    1. By Value
  3. In-house Manufacturing
    1. By Value
4. By Workflow
  1. Introduction
    1. Workflow By Value
  2. Cell Processing
    1. By Value
  3. Cell Banking
    1. By Value
  4. Fill & Finish Operations
    1. By Value
  5. Raw Material Testing
    1. By Value
  6. Vector Production
    1. By Value
  7. Other Workflows
    1. By Value
5. By Process
  1. Introduction
    1. Process By Value
  2. Upstream Processes
    1. By Value
  3. Downstream Processes
    1. By Value
6. By End-User
  1. Introduction
    1. End-User By Value
  2. Pharmaceutical Companies
    1. By Value
    2. Small Size
      1. Small Size By Value
    3. Medium Size
      1. Medium Size By Value
    4. Large Size
      1. Large Size By Value
  3. Biopharmaceutical / Biotechnological Companies
    1. By Value
    2. Small Size
      1. Small Size By Value
    3. Medium Size
      1. Medium Size By Value
    4. Large Size
      1. Large Size By Value
  4. Contract Manufacturing Organizations
    1. By Value
    2. Small Size
      1. Small Size By Value
    3. Medium Size
      1. Medium Size By Value
    4. Large Size
      1. Large Size By Value
7. By Technology Type
  1. Introduction
    1. Technology Type By Value
  2. Fluorescence-Activated Cell Sorting (FACS)
    1. By Value
  3. Enzyme-Linked Immunosorbent Assay (ELISA)
    1. By Value
  4. Chromatography
    1. By Value
  5. Next-Generation Sequencing (NGS)
    1. By Value
  6. Polymerase Chain Reaction (PCR)
    1. By Value
  7. Others
    1. By Value
Canada

Competitive Landscape

North America Cell and Gene Therapy Manufacturing QC Market Share By Players
M&A Agreements & Collaboration Analysis

Market Players Assessment

Lonza
1. Overview
2. Business Information
3. Revenue
4. ASP
5. SWOT Analysis
6. Recent Developments
Pharmaron
Eurofins Scientific
Merck KGaA
Catalent Inc.
Charles River Laboratories
Thermo Fisher Scientific Inc.
WuXi AppTec
BioAgilytix Labs
Alcami Corporation
IQVIA Inc.
SGS Société Générale de Surveillance SA
and others.

Research Methodology

Research Data
1. Secondary Data
  1. Major secondary sources
  2. Key data from secondary sources
2. Primary Data
  1. Key data from primary sources
  2. Breakdown of primaries
3. Secondary And Primary Research
  1. Key industry insights
Market Size Estimation
1. Bottom-Up Approach
2. Top-Down Approach
3. Market Projection
Research Assumptions
1. Assumptions
Limitations
Risk Assessment

Appendix

Discussion Guide
Customization Options
Related Reports

Disclaimer

Related Reports

Cell and Gene Therapy Market

Global Report

Cell and Gene Therapy Market Size The global cell and gene therapy market size was valued at USD 30.27 billion in 2024 and is projected to reach from USD 37.14 billion in 2025 to USD 190.82 billion by 2033, expanding at a&nb

Buy Now

Purchase Benefits

Eligible for a free updated report next year
Completely customizable scope
30% discount on your next purchase
Dedicated account manager
Query resolution within 24 hours
Permission to print the report

Table Of Content

Related Reports

Purchase Benefits

We are featured on :

Sample Details